open access

Vol 78, No 1 (2010)
EDUCATION
Published online: 2010-01-29
Submitted: 2013-02-22
Get Citation

Antileukotrienes in asthma - critical view

Wacław Droszcz
Pneumonol Alergol Pol 2010;78(1):60-67.

open access

Vol 78, No 1 (2010)
EDUCATION
Published online: 2010-01-29
Submitted: 2013-02-22

Abstract

This article discusses the role of cysteinyl leukotrienes in asthma and addresses the problem of the use of leukotriene receptor antagonists (LTRA) in the treatment of asthma. The author points out that these drugs are inferior to inhaled corticosteroids and long acting beta agonists and should be used as "add on" drugs being a third choice in the management of asthma. Lack of response to LTRA has a genetic background. Side effects of LTRA therapy is discussed, particularly Churg-Strauss syndrome. According to the recent literature, LTRA monotherapy should not be applied. In general, the author suggests that there is a risk of LTRA overtreatment particularly in children.

Abstract

This article discusses the role of cysteinyl leukotrienes in asthma and addresses the problem of the use of leukotriene receptor antagonists (LTRA) in the treatment of asthma. The author points out that these drugs are inferior to inhaled corticosteroids and long acting beta agonists and should be used as "add on" drugs being a third choice in the management of asthma. Lack of response to LTRA has a genetic background. Side effects of LTRA therapy is discussed, particularly Churg-Strauss syndrome. According to the recent literature, LTRA monotherapy should not be applied. In general, the author suggests that there is a risk of LTRA overtreatment particularly in children.
Get Citation

Keywords

asthma; leukotrienes; receptor antagonists; clinical efficacy and side effects

About this article
Title

Antileukotrienes in asthma - critical view

Journal

Advances in Respiratory Medicine

Issue

Vol 78, No 1 (2010)

Pages

60-67

Published online

2010-01-29

Bibliographic record

Pneumonol Alergol Pol 2010;78(1):60-67.

Keywords

asthma
leukotrienes
receptor antagonists
clinical efficacy and side effects

Authors

Wacław Droszcz

References (57)
  1. Droszcz W. Epitafium dla kromonów? Lekarz. 2005; 3: 32–34.
  2. Kaczmarek J, Kuna P. Leki antyleukotrienowe jako alternatywa dla niskich dawek steroidów wziewnych w leczeniu astmy łagodnej u dzieci. Terapia. 2008; 16: 23–31.
  3. Wytyczne PTH i PTF dotyczące postępowania w astmie oskrzelowej. Raport Panelu ekspertów 04.2006.
  4. Gryglewski RJ, Panczenko B, Korbut R, et al. Corticosteroids inhibit prostaglandin release from perfused mesenteric blood vessels of rabbit and from perfused lungs of sensitized guinea pig. Prostaglandins. 1975; 10(2): 343–355.
  5. Sotito E, De Ca, Giannesid D, et al. Studies ob the induction of lipcortin-1 by glucocorticoids. Ann. I st Super Sanita. 1993; 29: 391–394.
  6. Barnes PJ. How corticosteroids control inflammation: Quintiles Prize Lecture 2005. Br J Pharmacol. 2006; 148(3): 245–254.
  7. Dworski R, Fitzgerald GA, Oates J, et al. Effect of oral prednisone on airway inflammatory mediators in atopic asthma. Am. J. Resp. Crit. Care Med. 1994; 149: 453–454.
  8. Sano A, Muñoz NM, Sano H, et al. Inhibition of cPLA2 translocation and leukotriene C4 secretion by fluticasone propionate in exogenously activated human eosinophils. Am J Respir Crit Care Med. 1999; 159(6): 1903–1909.
  9. Peters-Golden M, Thebert P. Inhibition by methylprednisolone of zymosan-induced leukotriene synthesis in alveolar macrophages. Am Rev Respir Dis. 1987; 135(5): 1020–1026.
  10. Oosterhoff Y, Overbeek SE, Douma R, et al. Lower leukotriene C(4) levels in bronchoalveolar lavage fluid of asthmatic subjects after 2.5 years of inhaled corticosteroid therapy. Mediators Inflamm. 1995; 4(6): 426–430.
  11. Grzanka A. Rozdział 4. Genetyka astmy i molekularne podstawy działania leków stosowanych w astmie. In: Droszcz W. ed. Astma. PZWL, Warszawa 2005.
  12. Dahlén B, Nizankowska E, Szczeklik A, et al. Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics. Am J Respir Crit Care Med. 1998; 157(4 Pt 1): 1187–1194.
  13. Malmstrom K, Rodriguez-Gomez G, Guerra J, et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group. Ann Intern Med. 1999; 130(6): 487–495.
  14. Israel E, Chervinsky PS, Friedman B, et al. Effects of montelukast and beclomethasone on airway function and asthma control. J Allergy Clin Immunol. 2002; 110(6): 847–854.
  15. Szefler SJ, Phillips BR, Martinez FD, et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol. 2005; 115(2): 233–242.
  16. Bleecker ER, Welch MJ, Weinstein SF, et al. Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma. J Allergy Clin Immunol. 2000; 105(6 Pt 1): 1123–1129.
  17. Barnes N, Thomas M, Price D, et al. The national montelukast survey. J Allergy Clin Immunol. 2005; 115(1): 47–54.
  18. Bocheńska-Marciniak M, Kupczyk M, Kuna P. Wpływ nontelukastu na objawy choroby u pacjentów z łagodną i umiarkowaną astmą przewlekłą: wyniki Nieinterwencyjnego Badania Obserwacyjnego. Alergia, Astma, Immonol. 2004; 9: 154–154.
  19. Robinson DS, Campbell D, Barnes PJ. Addition of leukotriene antagonists to therapy in chronic persistent asthma: a randomised double-blind placebo-controlled trial. Lancet. 2001; 357(9273): 2007–2011.
  20. Drazen JM, Yandava CN, Dubé L, et al. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat Genet. 1999; 22(2): 168–170.
  21. Lima JJ, Zhang S, Grant A, et al. Influence of leukotriene pathway polymorphisms on response to montelukast in asthma. Am J Respir Crit Care Med. 2006; 173(4): 379–385.
  22. Currie GP, Lee DKC. Uncertain biologic relevance of polymorphisms of leukotriene C4 synthase in asthma. J Allergy Clin Immunol. 2005; 115(1): 205.
  23. Kim JH, Lee SY, Kim HB, et al. TBXA2R gene polymorphism and responsiveness to leukotriene receptor antagonist in children with asthma. Clin Exp Allergy. 2008; 38(1): 51–54.
  24. Sampson AP, Siddigui S, Buchanan D, et al. Variant LTC4 synthase allele modifies cysteinyl leukotriene synthesis in cosinophils and predicts clinical response to zafirlukast. Thorax. 2000; 55(supl. 2): S28–S31.
  25. Sanak M, Kiełbasa B, Bochenek G, et al. Biosynthesis of cysteinyl-leucotrienes in aspirin-intolerant asthma. Clin Exp Allergy. 1999; 29(3): 306–313.
  26. CHURG J, STRAUSS L. Allergic granulomatosis, allergic angiitis, and periarteritis nodosa. Am J Pathol. 1951; 27(2): 277–301.
  27. Masi AT, Hunder GG, Lie JT, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum. 1990; 33(8): 1094–1100.
  28. Canron M, Beynon HL. Churg-Strauss Syndrome. Thorax . 2000; 55: 870–877.
  29. Loughlin JE, Cole JA, Rothman KJ, et al. Prevalence of serious eosinophilia and incidence of Churg-Strauss syndrome in a cohort of asthma patients. Ann Allergy Asthma Immunol. 2002; 88(3): 314–325.
  30. Tworek D, Kuna P. Związek między zespołem Churg-Strauss a lekami antyleukotrienowymi. Merk. Lek. 2005; XIX: 202–205.
  31. Świerczyński M, Mastalerz L, Niżankowska-Mogrelnicka EA. case report of Churg-Strauss Syndrome and montelukast therapy. Int Rev Allergy Clin Immunol. 2002; 8: 9.
  32. Hauser T, Mahr A, Metzer C, et al. he leukotriene antagonist montelukast and risk of Churg-Strauss Syndrome: a case crossover study. Thorax. 2008: 1–14.
  33. Garcia-Marcos L, Schuster A, Perez-Yarza E. Benefit-Risk Assessment of Antileukotrienes in the Management of Asthma. Drug Safety. 2003; 26(7): 483–518.
  34. Pagnoux C, Guilpain P, Hauser T, et al. Churg-Strauss Syndrome and Leukotriene-Modifying Agents. Clinical Pulmonary Medicine. 2004; 11(6): 349–354.
  35. Green R, Vayonis A. Churg-Strauss syndrome after zafirlukast in two patients not receiving systemic steroid treatment. The Lancet. 1999; 353(9154): 725–726.
  36. Wechsler ME, Garpestad E, Flier SR, et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast. JAMA. 1998; 279(6): 455–457.
  37. Lipworth B, Wilson A. Montelukast and Churg-Strauss syndrome. Thorax. 2001; 56: 805–806.
  38. Bjermer L. Montelukast w leczeniu astmy jako choroby ogólnoustrojowej (tłumaczenie). Expert Rev Immunol. 2005; 3: 325–326.
  39. Knorr B, Franchi LM, Bisgaard H. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics. 2001; 43: 529–533.
  40. Migoya E, Kearns GL, Hartford A, et al. Pharmacokinetics of montelukast in asthmatic patients 6 to 24 months old. J Clin Pharmacol. 2004; 44(5): 487–494.
  41. FDA investigates possible suicide risk link with montelukast, FDA, Home Page.
  42. Peters SP, Anthonisen N, Castro M, et al. American Lung Association Asthma Clinical Research Centers. Randomized comparison of strategies for reducing treatment in mild persistent asthma. N Engl J Med. 2007; 356(20): 2027–2034.
  43. Światowa strategia rozpoznawania, leczenia i prewencji astmy. 01.2008,.
  44. Jenkins CR, Thien FCK, Wheatley JR, et al. Traditional and patient-centred outcomes with three classes of asthma medication. Eur Respir J. 2005; 26(1): 36–44.
  45. Montuschi P, Mondino C, Koch P, et al. Effects of a leukotriene receptor antagonist on exhaled leukotriene E4 and prostanoids in children with asthma. J Allergy Clin Immunol. 2006; 118(2): 347–353.
  46. Ducharme FM. Anti-leukotrienes as add-on therapy to inhaled glucocorticoids in patients with asthma: systematic review of current evidence. BMJ. 2002; 324(7353): 1545–1548.
  47. Jat GC, Mathew JL, Singh M. Treatment with 400 microg of inhaled budesonide vs 200 microg of inhaled budesonide and oral montelukast in children with moderate persistent asthma: randomized controlled trial. Ann Allergy Asthma Immunol. 2006; 97(3): 397–401.
  48. Stanowiska ekspertów w sprawie zmiany wskazania do stosowania preparatu Singulair 4 i Singulair 5 (montelukast sodu MSD), 2007. Materiał grantu edukacyjnego MSI).
  49. Dempsey OJ, Fowler SJ, Wilson A, et al. Effects of adding either a leukotriene receptor antagonist or low-dose theophylline to a low or medium dose of inhaled corticosteroid in patients with persistent asthma. Chest. 2002; 122(1): 151–159.
  50. Bacharier LB, Boner A, Carlsen KH, et al. European Pediatric Asthma Group. Diagnosis and treatment of asthma in childhood: a PRACTALL consensus report. Allergy. 2008; 63(1): 3–34.
  51. Mastalerz L, Gawlewicz-Mroczka A, Nizankowska E, et al. Protection against exercise-induced bronchoconstriction by montelukast in aspirin-sensitive and aspirin-tolerant patients with asthma. Clin Exp Allergy. 2002; 32(9): 1360–1365.
  52. Grzelewski T, Stelmach I, Stelmach I, et al. Effect of different antiasthmatic treatments on exercise-induced bronchoconstriction in children with asthma. J Allergy Clin Immunol. 2008; 121(2): 383–389.
  53. Adelroth E, Inman MD, Summers E, et al. Prolonged protection against exercise-induced bronchoconstriction by the leukotriene D4-receptor antagonist cinalukast. J Allergy Clin Immunol. 1997; 99(2): 210–215.
  54. Robuschi M, Riva E, Fuccella LM, et al. Prevention of Exercise-induced Bronchoconstriction by a New Leukotriene Antagonist (SK&F 104353): A Double-Blind Study Versus Disodium Cromoglycate and Placebo. American Review of Respiratory Disease. 1992; 145(6): 1285–1288.
  55. Kemp JP, Dockhorn RJ, Shapiro GG, et al. Montelukast once daily inhibits exercise-induced bronchoconstriction in 6- to 14-year-old children with asthma. J Pediatr. 1998; 133(3): 424–428.
  56. Szczeklik A, Niżankowska E, Sanak M, et al. Leukotrienes and antuleukotriene drugs in bronchial astma with special reference to aspirin intolerance. Eur Resp Rev. 2000; 10: 280–282.
  57. Mastalerz L, Nizankowska E, Sanak M, et al. Clinical and genetic features underlying the response of patients with bronchial asthma to treatment with a leukotriene receptor antagonist. Eur J Clin Invest. 2002; 32(12): 949–955.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl